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Hepatic lipocalin 2 promotes liver 
fibrosis and portal hypertension
Jiegen Chen1,11, Josepmaria Argemi2,11, Gemma Odena1, Ming‑Jiang Xu3, Yan Cai3, 
Veronica Massey1, Austin Parrish4, Rajanikanth Vadigepalli4, Jose Altamirano5, 
Joaquin Cabezas6, Pere Gines7, Juan Caballeria7, Natasha Snider8, Pau Sancho‑Bru7, 
Shizuo Akira9, Ivan Rusyn10, Bin Gao3 & Ramon Bataller1,2*
Advanced fibrosis and portal hypertension influence short‑term mortality. Lipocalin 2 (LCN2) regulates 
infection response and increases in liver injury. We explored the role of intrahepatic LCN2 in human 
alcoholic hepatitis (AH) with advanced fibrosis and portal hypertension and in experimental mouse 
fibrosis. We found hepatic LCN2 expression and serum LCN2 level markedly increased and correlated 
with disease severity and portal hypertension in patients with AH. In control human livers, LCN2 
expressed exclusively in mononuclear cells, while its expression was markedly induced in AH livers, 
not only in mononuclear cells but also notably in hepatocytes. Lcn2−/− mice were protected from 
liver fibrosis caused by either ethanol or  CCl4 exposure. Microarray analysis revealed downregulation 
of matrisome, cell cycle and immune related gene sets in Lcn2−/− mice exposed to  CCl4, along with 
decrease in Timp1 and Edn1 expression. Hepatic expression of COL1A1, TIMP1 and key EDN1 system 
components were elevated in AH patients and correlated with hepatic LCN2 expression. In vitro, 
recombinant LCN2 induced COL1A1 expression. Overexpression of LCN2 increased HIF1A that in turn 
mediated EDN1 upregulation. LCN2 contributes to liver fibrosis and portal hypertension in AH and 
could represent a new therapeutic target.
Excessive alcohol consumption is responsible for 3.8% of global  mortality1. Among alcohol-induced organ dam-
age, alcohol-related liver disease (ALD) is a major cause of morbidity and  mortality2. ALD progresses from fatty 
liver to hepatic inflammation, progressive fibrosis and hepatocellular carcinoma. Moreover, patients with heavy 
alcohol use and underlying ALD can present episode(s) of alcoholic hepatitis (AH), which is the most severe form 
of ALD. AH is characterized by an abrupt development of jaundice, liver failure and portal  hypertension3. Mor-
tality in AH patients remains very high, and targeted therapies beyond corticosteroids are urgently needed. We 
previously found that advanced fibrosis and portal hypertension determine the prognosis of  AH4,5. Uncovering 
the cellular and molecular mechanisms underlying fibrosis in AH could favor the development of novel therapies.
LCN2, also known as neutrophil gelatinase-associated lipocalin (NGAL), is a secreted 25-kDa glycopro-
tein belonging to lipocalin  superfamily6,7 first identified as a protein stored in specific granules of human 
 neutrophils8. LCN2 has multiple functions in regulation of innate  immunity9, cell  proliferation10,  apoptosis11, 
 metabolism12,13 and tumor  metastasis14. LCN2 is a pro-inflammatory cytokine and a useful biomarker of acute 
kidney  injury10,15. Hepatic LCN2 is markedly increased in experimental liver injury and its increase is mediated by 
open
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pro-inflammatory  cytokines16. The role of LCN2 in liver inflammation is inconsistent. Mice lackcing Lcn2 show 
more liver injury after  CCl4, ConA and LPS  exposure17. However, LCN2 deficiency protects against alcohol and 
diet-induced liver  injury18,19. The relevance of LCN2 in liver fibrogenesis and portal hypertension is unknown. 
Activation of hepatic stellate cell is a landmark in fibrosis because these cells turn into the primary source of 
extracellular matrix in liver upon injury. In vitro, recombinant LCN2 is reported to induce type 1 collagen 
protein expression in human fibroblasts in a dose-dependent  fashion20. In cultured mouse collecting duct cells, 
silencing of LCN2 receptor represses transforming growth factor beta 1 (TGFβ1) signaling and α-smooth muscle 
actin  expression21. These findings suggest that LCN2 could act as an extracellular stimulus to modulate trans-
differentiation of quiescent retinol-storing cells into fibrogenic myofibroblasts. We hypothesized that hepatic 
LCN2 was involved in activation of HSCs in AH patients.
Here, we describe the association of LCN2 hepatic and circulatory levels with liver fibrosis, portal hyperten-
sion and disease severity in patients with AH. Using ethanol-fed and  CCl4-induced liver fibrosis in Lcn2-deficient 
mice, we demonstrate that LCN2 plays a key role in liver fibrogenesis and portal hypertension. Moreover, we 
provide evidence that this effect is mediated by hypoxia-induced factor 1 (HIF1A)/EDN1 axis.
Results
LCN2 gene expression and serum levels in AH: correlation with disease severity, liver fibro‑
sis and portal hypertension. Analysis of microarray data from patients with  AH22 showed that hepatic 
LCN2 gene expression is one of the most up-regulated genes in the whole transcriptome (Supplementary Fig-
ure 1a). Confirmatory real-time qPCR showed a dramatic up-regulation of LCN2 in AH patients, which was not 
observed in other liver diseases including nonalcoholic steatohepatitis (NASH), HCV-induced chronic hepatitis 
and HCV-induced compensated cirrhosis. In patients with AH, serum LCN2 levels correlated with the hepatic 
LCN2 mRNA expression (Fig. 1a). The results suggest that hepatic LCN2 gene expression is an important source 
of circulating LCN2 in patients with AH.
To assess the clinical relevance of LCN2, the association of LCN2 gene expression with parameters indica-
tive of disease prognosis was evaluated. We found that hepatic LCN2 gene expression positively correlated with 
the main prognostic scores in patients with AH, including the Age/Bilirubin/International normalized ratio/
Creatinine (ABIC) score (r = 0.41, p = 0.002) and the Model for End-stage Liver Disease (MELD) score (r = 0.41, 
p = 0.002) (Fig. 1b). Moreover, serum level of LCN2 positively correlated with AH disease severity, as assessed 
by the ABIC score (r = 0.53, p = 0.0002) and MELD score (r = 0.43, p = 0.004) (Fig. 1c).
It is well-established that Gram-negative bacterium-derived LPS is a major driver of  AH23. We found that 
hepatic LCN2 gene expression in patients with AH closely correlated with circulating LPS levels (r = 0.55, 
p = 0.0002) (Fig. 1d). Furthermore, in vivo, both hepatic Lcn2 mRNA expression and serum LCN2 increased 
after LPS injection in mice (Supplementary Figure 1b). LPS exposure induced LCN2 expression around sixfold 
in precision-cut rat liver slices (Supplementary Figure 1c). In contrast, we found that gene expression levels 
of hepatic LCN2 receptors (i.e. SLC22A7 and LRP2) were slightly increased in AH patients (Supplementary 
Figure 1d and e).
Importantly, hepatic LCN2 mRNA expression in patients with AH closely correlated with the degree of portal 
hypertension (r = 0.47, p = 0.0005) (Fig. 1e), a major pathophysiological event. The analysis of RNA-sequencing 
data from a similar cohort of AH patients revealed that hepatic LCN2 gene expression was highly associated 
with two extracellular matrix genes: COL1A1 (r = 0.81, p < 0.001) and TIMP1 (r = 0.90, p < 0.001) (Fig. 1f). These 
results strongly suggest that LCN2 may play a pathogenic role in liver fibrosis and portal hypertension in patients 
with AH.
Hepatocyte LCN2 expression is highly induced in human AH but not in mouse ALD model. To 
determine the cell source of LCN2 in AH, we performed IHC in the liver sections from normal controls and 
patients with AH. In normal livers, LCN2 exclusively expressed in mononuclear cells while its expression was 
markedly increased in AH livers, not only in inflammatory cells but also notably in hepatocytes (Fig. 2a). Mac-
rophages have been described as LCN2 secreting cells in  mice9 and Kupffer cells are resident macrophages in 
human liver. Concordantly, immunofluorescence staining showed that LCN2 expression co-localized with 
CD68, a human macrophage cell marker (Fig. 2b). In line with these findings, cultured hepatocytes LCN2 mRNA 
expression induced by LPS dose-dependently. In macrophages LCN2 gene expression increased markedly with 
LPS treatment (Supplementary Figure 2a and b).
We next assessed LCN2 expression in mice subjected to sub-acute and chronic experimental ALD. For this 
purpose, mice were fed an ethanol diet plus one binge of ethanol for 10-day or 8-week, as previously  described24. 
Upon ethanol treatment, hepatic Lcn2 mRNA expression significantly increased in both models. Serum LCN2 
level was higher in the 8-week ethanol-fed mice (Fig. 2c). LCN2-positive macrophages (Fig. 2d) and neutrophils 
(Supplementary Figure 2c) were increased in 8-week ethanol-fed mice, but the increase of LCN2 expression 
not shown in hepatocytes. Take together these results suggest a species discrepancy and that ethanol exposure 
increases hepatic LCN2 expression only from inflammatory cells in mice. However, in human AH, LCN2 not 
only from inflammatory cells but also highly induced in hepatocytes.
LCN2 ablation attenuates  CCl4‑induced fibrosis by mediating ECM deposition and G‑pro‑
tein‑coupled receptor (GPCR) signaling. To explore the potential role of LCN2 in the development 
of liver fibrosis, WT and Lcn2−/− mice were exposed to chronic ethanol for 8 weeks plus binge administration. 
Even in the absence of overt fibrosis in this model (Supplementary Figure 3a), we found that Timp1 expres-
sion, an important pro-fibrogenic effector, was significantly decreased in ethanol-fed Lcn2−/− mice compared 
with ethanol-fed WT mice, pointing to this metalloprotease inhibitor as an early mechanism in alcoholic liver 
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fibrosis (Supplementary Figure 3b). To further study the role of LCN2 in liver fibrosis, we used  CCl4 for 4 weeks 
to induce advanced fibrosis in WT and Lcn2-/– mice. Notably, Lcn2–/– mice developed less fibrosis accumula-
tion compared with WT littermates (Fig. 3a). The induction of expression of Col1a1 and the genes involved in 
extracellular matrix turnover, such as alpha-smooth muscle actin (Acta2), Timp1 and Mmp2 were abrogated in 
mice lacking Lcn2 (Fig. 3b).
To dissect the molecular mechanisms that mediating LCN2-induced fibrogenic effects in the injured liver, 
we performed transcriptome profiling analysis in the liver of Lcn2–/– and WT mice treated with  CCl4. Absence 
of Lcn2 gene attenuated the transcriptome changes induced by  CCl4. The number of significantly up-regulated 
genes (1,346 in WT vs 1,067 in Lcn2−/−) and downregulated genes (991 in WT vs 562 in Lcn2−/−) was significantly 
decreased in mice lacking Lcn2 gene. Gene set enrichment analysis of the differentially expressed genes (GSEA) 
revealed, among downregulated functions, an enrichment of gene sets related to matrisome, cell cycle, develop-
ment and immune response (Fig. 3c). A detailed analysis of these gene sets showed the lack of upregulation of 
multiple collagen genes and genes encoding ECM adhesion glycoproteins in  CCl4-treated Lcn2−/− mice (Fig. 3d). 
Another pathway affected by Lcn2 knockout was G-protein-coupled receptors (GPCR) signaling (Fig. 3e). Defects 
in GPCR regulation have severe consequences affecting GPCR-stimulated vascular  responses25. These results 
suggest that  CCl4-mediated upregulation of ECM and endothelin system genes are dependent on Lcn2 gene 
expression and LCN2 is a key pathogenic regulator in mouse  CCl4-induced liver fibrosis.
Figure 1.  LCN2 gene expression and serum levels of LCN2 increase in patients with AH and correlate with the 
disease severity, portal hypertension and pro-fibrogenic gene expression. (a) Hepatic LCN2 mRNA expression 
was measured by qPCR in normal controls (n = 8), NASH (n = 14), HCV (n = 10), cirrhosis (n = 13) and patients 
with AH (n = 55). Serum LCN2 level was determined by ELISA in normal controls (n = 20), HCV (n = 8), 
cirrhosis (n = 10) and patients with AH (n = 45). (b) Hepatic LCN2 gene expression correlated with ABIC 
and MELD scores. (c) Serum level of LCN2 correlated with ABIC and MELD scores. (d) Hepatic LCN2 gene 
expression correlated with the level of circulating LPS. (e) Hepatic LCN2 gene expression correlated with the 
degree of portal hypertension. (f) Hepatic LCN2 mRNA expression correlated with COL1A1 and TIMP1 gene 
expression. *p < 0.05; **p < 0.01 by one-way ANOVA.
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Endothelin system gene expression is increased in mouse ALD and human AH. We hypoth-
esized that LCN2 could affect splanchnic vascular tone through regulation of vasoconstrictors and vasodilators 
related to GPCR signaling. ET1, a potent vasoconstrictor, is upregulated in human  cirrhosis26,27. ET1 activity is 
regulated by endothelin converting enzymes 1 and 2 (ECE1 and ECE2) and its action is mediated by two different 
GPCRs: endothelin receptor Type A (EDNRA) and Type B (EDNRB). Strikingly, mouse Edn1 gene expression 
was markedly elevated in WT compared with Lcn2−/− mice upon  CCl4 treatment (Fig. 4a). We then explored the 
expression of the endothelin system gene in 8-week plus binge ethanol-fed mice. In this model, chronic etha-
nol exposure was sufficient to induce Edn1 expression in WT but not in Lcn2−/− mice (Fig. 4b). Furthermore, 
we studied the expression of endothelin system genes in the liver of patients with AH. RNA-sequencing data 
showed that the expression of EDN1, ECE1 and EDNRA was specifically increased in AH livers compared with 
normal livers and other diseased livers (Fig. 4c). Interestingly, the levels of these transcripts were highly corre-
lated with hepatic LCN2 expression (Fig. 4d). Circulating ET1 concentration was higher in AH patients than in 
normal controls and HCV patients (Fig. 4e). These results indicate that the endothelin system gene expression 
is activated in mouse and human after alcohol exposure and is tightly correlated with LCN2 gene expression in 
the liver.
LCN2‑HIF1Α axis regulates endothelin expression in human hepatic stellate cells (HSCs). We 
next explored whether LCN2 could induce the synthesis of ET1 in the human liver cells. In patients with AH, 
immunofluorescence staining showed that both hepatocytes and HSCs expressed SLC22A17 (LCN2 receptor) 
(Fig. 5a). In vitro, we used adenovirus-mediated overexpression of LCN2 in human primary hepatocytes (HPHs) 
and HepG2 cells. RNA-sequencing data showed that the expression profiles were not significantly altered in both 
transduced cells (Supplementary Figure 4a). We then investigated the effect of LCN2 on cultured human pri-
mary HSCs. Treatment of HSCs with recombinant LCN2 increased the expression level of gene related to HSC 
activation (Fig. 5b) and increased intracellular free calcium concentration (61.7 ± 6.0 nM), indicating the pres-
ence of active receptors (Fig. 5c and Supplementary Table 2). Furthermore, adenovirus-mediated overexpres-
sion of LCN2 in the HSCs increased expression of END1 along with HSCs activation marker ACTA2 and other 
vasoconstrictor factors like angiotensinogen (AGT ) (Fig. 5d).
We finally explored the molecular mechanism involved in LCN2-induced END1 up-regulation in the HSCs. 
In breast cancer cell LCN2 can induce HIF1A expression, which is an important transcriptional factor mediated 
EDN1 gene expression in endothelial  cells28,29. Therefore, we used human LCN2 over-expression adenovirus to 
infect the HSCs and Western blot results showed that LCN2-overexpression induced HIF1A expression (Fig. 5e). 
Transfecting specific HIF1A siRNA into the HSCs to knockdown HIF1A expression (Supplementary Figure 4b), 
we found the decreased EDN1 mRNA expression in the cells (Fig. 5f). Consistently, ChIP-qPCR data showed 
the increased binding activity of HIF1A to the promoter region of EDN1 gene in HSCs-overexpressing LCN2 
(Fig. 5g). Taken together, these results indicate LCN2 induces the increase of EDN1 expression mediated by 
HIF1A in human HSCs.
Discussion
We previously demonstrated that the presence of advanced fibrosis/cirrhosis in patients with AH confers a bad 
 prognosis4. Complications in AH are due to liver failure and the development of severe portal hypertension. It is 
known that severe fibrosis is a key determinant of portal hypertension. In fact, previous reports have shown that 
the degree of portal hypertension, as assessed by HVPG, correlates with short-term  survival30. Most investigations 
of the pathogenesis of AH have focused on intrahepatic inflammation and hepatocellular failure. The current 
study was undertaken to identify druggable molecular drivers of fibrogenesis and portal hypertension in AH. 
Through liver transcriptome analysis, we identified LCN2 as one of the most up-regulated genes in AH  patients22. 
Recent studies showing that liver-derived LCN2 is a prognostic factor in a series of patients with acute-on-chronic 
liver failure, half of them being AH  patients31. We provide evidence that LCN2 is massively overexpressed in the 
liver from patients with AH and its expression correlates with the degree of fibrosis and portal hypertension. 
Because some pro-inflammatory mediators also play a role in fibrosis development and the progression of portal 
 hypertension32, we analyzed the potential pro-fibrogenic role of LCN2 in human AH and experimental animal 
model. Animal models of ethanol-induced liver injury do not completely develop many of the key features of 
advanced ALD, including the development of massive fibrosis and liver  failure3. To overcome this limitation, 
we assessed the functional role of LCN2 in human samples and in mice subjected to a well characterized model 
of liver fibrosis. The findings that hepatic LCN2 expression closely correlated with disease severity (i.e. ABIC 
and MELD scores), the degree of portal hypertension (i.e. levels of HVPG) and the expression of key fibrogenic 
genes (i.e. COL1A1, TIMP1) highly suggest a pathogenic role for LCN2 in AH. Mouse lacking LCN2 showed 
Figure 2.  LCN2 expression in human AH and mouse ALD. (a) Representative IHC images of LCN2 expression 
in the liver from normal control (Ctrl, n = 9) and patients with AH (AH, n = 6). (b) Representative IF images of 
co-staining of LCN2 and CD68 expression in the biopsies from control (Ctrl, n = 6) and patient with AH (AH, 
n = 4). Hoechst 33,258 (blue) used to label nuclei, TSA-Cy5 visualized LCN2 (red) and TSA-Cy3 visualized 
CD68 (green). Overlay of LCN2 and CD68 showed dual expression (yellow). (c) Hepatic Lcn2 expression and 
serum levels of LCN2 in mice after 10-day (grey) or 8-week (black) ethanol exposure plus binge (n = 4–5). (d) 
Representative IF images of dual staining showed co-localization of LCN2 and F4/80 expression in the liver 
from pair-fed and ethanol-fed mice (n = 4–5). Hoechst 33,258 (blue) used to label nuclei, TSA-Cy5 visualized 
LCN2 (red) and TSA-Cy3 visualized F4/80 (green). Overlay of LCN2 and F4/80 showed dual expression (blue/
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Figure 3.  Lcn2−/− mice are protected from chronic  CCl4 exposure induced liver fibrosis. (a) BALB/c WT and 
Lcn2−/− mice exposed to  CCl4 for 4 weeks and representative images of collagen fibers stained with Sirius red 
(n = 11–19). (b) The surface area stained with Sirius red was quantitated using digital image analysis. Col1a1, 
Acta2, Timp1, Mmp2 and Tgfb1 gene expression was quantified by qPCR (n = 14–20). (c) Gene set enrichment 
analysis for WT and Lcn2−/− mice treated with  CCl4 and functional pathways identified (n = 4–5). (d) Heatmap 
of genes of Integrin pathway that were differentially regulated in WT and Lcn2−/− mice treated with  CCl4 
(n = 4–5). (e) Heatmap of genes of GPCR binding pathway differentially regulated in WT and Lcn2−/− mice 
treated with  CCl4 (n = 4–5). *p < 0.05 by one-way ANOVA. Scale bar: 100 μm.
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an attenuated fibrogenic response to liver injury. These results reveal a novel pathogenic function for LCN2 in 
chronic liver diseases with potential therapeutic implications.
Our studies clearly demonstrate that the cell sources of LCN2 in human advanced ALD are not only from 
inflammatory cells but also from hepatocytes. This notion is important since reprogrammed hepatocytes are 
able to produce pro-inflammatory and fibrogenic mediators such as IL-8 and now  LCN233. The fact that fibrosis 
in AH is characterized by a pericellular pattern highly suggest that hepatocytes play a major role in fibro-
sis  development34. Maneuvers aimed at preventing the expression and secretion of fibrogenic mediators by 
hepatocytes may have beneficial effects. Interestingly, we also show that LPS mediates LCN2 overexpression in 
hepatocytes. This finding confirms previous data from our group showing that LPS is an important mediator in 
AH and supports the notion that targeting LPS could have beneficial effects in  AH35,36. It is notable that LCN2 
gene is expressed in early stages of rat primary HSC activation. In these primary cells, protein levels of LCN2 
were highest when HSCs were fully  activated37. These findings strongly suggest that LCN2 could be a fibrogenic 
mediator in the chronically damaged liver.
We partially uncovered the mechanisms of LCN2-induced fibrosis and portal hypertension in AH. In micro-
array analysis in mice lacking Lcn2 gene with attenuated fibrogenic response, we identified ET1 as a potential 
mediator of LCN2 in AH. Previous studies have shown that ET1 is a fibrogenic factor that promotes portal 
hypertension in the damaged  liver38,39. In fact, plasma ET1 levels are elevated in patients with cirrhosis, and 
there is a positive association with poor prognosis and increased portal  pressure26,27. The sources of ET1 in the 
damaged liver include endothelial cells and  HSCs40–43. Because HSCs are liver-specific pericytes that play a key 
Figure 4.  Expression of endothelin system genes increases in mouse experimental model and human AH. (a) 
Hepatic endothelin system gene expression was confirmed by qPCR from WT and Lcn2−/− mice exposed to 
 CCl4 (n = 4–6). (b) Hepatic endothelin system gene expression from WT and Lcn2−/− mice after 8-week ethanol 
plus binge exposure. (n = 4 for each group). (c) Human liver biopsies for RNA-sequencing analysis of EDN1, 
ECE1 and EDNRA expression included multiple etiologies of liver tissues representing control liver (n = 10), 
NASH (n = 9), HCV (n = 10), compensated cirrhosis (n = 9) and AH (n = 29). (d) Correlation of hepatic LCN2 
and EDN1, ECE1 and EDNRA expression in AH patients. (e) Circulating ET1 concentration was quantified by 
ELISA in serum of patients with multiple etiologies of liver disease. *p < 0.05; **p < 0.01 by one-way ANOVA.
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role linking fibrosis and portal hypertension, we demonstrated that LCN2 promotes EDN1 synthesis in HSCs 
during liver fibrogenesis. While wild type mice with advanced fibrosis showed a marked increase in Edn1 hepatic 
expression, Lcn2 deficient mice did not show such upregulation. Notably, LCN2 also mediated the expression of 
key genes for ET1 generation and biological actions, including Ece2 or Ednra. These results suggest a key role of 
LCN2 in ET1 regulation in the fibrotic liver. Interestingly, chronic ethanol plus binge model showed an increase 
in the expression of Edn1. In this model, LCN2 was again necessary for Edn1 upregulation. Our results indicate 
that alcohol exposure can stimulate the LCN2-mediated expression of Edn1. In this study, due to technique 
Figure 5.  LCN2-HIF1A pathway regulates EDN1 expression in human HSCs. (a) Representative IF images of 
co-localization LCN2 receptor (SLC22A17) and α-SMA in AH livers. Hoechst 33,258 (blue) was used to label 
nuclei, TSA-Cy5 visualized SLC22A17 (red) and TSA-Cy3 visualized α-SMA (green). Overlay of SLC22A17 
and α-SMA showed co-expression (yellow). (b) LX-2 cells were exposed to 50 µM human recombinant LCN2. 
ACTA2, COL1A1, AGT and EDN1 gene expression was measured by qPCR (n = 3). (c) Intracellular free calcium 
concentration of LX-2 cells was detected using Fura-2 fluorescence. (d) Human primary HSCs transduced with 
adenovirus-mediated overexpression of GFP or LCN2. ACTA2, COL1A1, AGT and EDN1 gene expression were 
measured by qPCR (n = 3). (e) Human primary HSCs transduced with adenovirus-mediated overexpression 
of GFP or LCN2. HIF1A expression was detected by Western Blot (n = 3) and the original blots are presented 
in Supplementary Figure 5. (f) HIF1A siRNA was transfected into human primary HSCs and EDN1 gene 
expression measured by qPCR (n = 3). (g) ChIP-qPCR was used to detect binding affinity of HIF1A to the EDN1 
gene promoter in human primary HSCs (n = 3). *p < 0.05 by two-tailed Student’s t test. Scale bar: 100 μm.
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difficulties in measuring portal pressure in  CCl4-treated mice, we could not confirm the effect of LCN2 on portal 
hypertension in experimental models.
Previous studies in alcohol-induced steatohepatitis in mice unfolded the role of HIF1A as a key inducer 
of liver  injury44. Ethanol and acetaldehyde are reported to induce HIF1A -mediated expression of Edn1 in 
endothelial cells (28). Our study showed LCN2-overexpression in HSC induced HIF1A expression. Importantly, 
decreasing HIF1A expression levels in HSC resulted in reduced EDN1 expression. The binding activity of HIF1A 
to the promoter region of EDN1 increased in HSCs overexpressing LCN2. ET1 could be one of HIF1A targets 
responsible for its downstream actions in fibrosis and  angiogenesis45. Our results add new evidence to the role 
of HIF1A in liver injury.
In summary, our results suggest that LCN2 massive hepatic expression in patients with AH could favor fibrosis 
and portal hypertension, two of the main predictors of patients’ morbidity and mortality. The LCN2-HIF1A-ET1 
axis is a potential new mechanism of hepatocyte-HSC communication in chronic ethanol-induced liver damage. 
Further studies should evaluate if drugs interfering with LCN2 synthesis and/or biological actions have beneficial 
effects in patients with this severe clinical condition.
Materials and methods
Human subjects. All human biospecimens were obtained from the National Institute on Alcohol Abuse 
and Alcoholism (NIAAA)-funded InTeam Consortium Human Biorepository Core (University of Pittsburgh, 
PA). All human studies conformed to the ethical guidelines of the Declaration of Helsinki and were approved by 
the Institutional Review Board of the University of Pittsburgh. Patients with biopsy-proven AH as well as nor-
mal controls were included as described in detail  previously46. Informed consent was obtained from all human 
participants. The clinical characteristics of the patients included in Supplementary Table 1.
Experimental animal studies. All the experiments reported in this study were adherent to the Animal 
Research: Reporting of In Vivo Experiments (ARRIVE) guidelines. The protocols for animal housing, treatment 
and euthanasia were approved by the Institutional Animal Care and Use Committee of the University of North 
Carolina at Chapel Hill, and the NIAAA Animal Care and Use Committee and the Institutional Animal Care 
and Use Committee of Texas A&M University.
LPS injection. Eight-week-old male BALB/c mice were injected intravenously by a single dose of LPS at 10 mg/
kg body weight. Mice were sacrificed at 6 h after  injection35.
Subacute and chronic ethanol exposure plus binge. Lcn2–/– mice were back-crossed to a C57BL/6N background 
for at least nine generations. Mice were maintained on a normal chow diet in the NIAAA animal facility. Eight- to 
ten-week-old male LCN2–/– and C57BL/6N mice were initially fed a controlled Lieber-DeCarli diet ad libitum 
for 5 days to acclimatize them to a liquid diet. Subsequently the ethanol-fed groups were allowed free access for 
10 days or 8 weeks to an ethanol diet containing 5% (vol/vol) ethanol. Binge feeding was a single dose of ethanol 
(5 g/kg body weight) via gavage in the early morning. Mice were sacrificed 9 h  later47,48.
Chronic CCl4 treatment. BALB/c wild type and Lcn2−/− mice were generously provided by Dr. Shizuo Akira 
from Osaka University, Japan. Lcn2−/− mice were generated on a 129/Ola X C57BL/6 (B6.129) background as 
described  previously9 and backcrossed to BALB/c mice for at least nine  generations49. Six- to eight-week-old 
male BALB/c WT or Lcn2−/− mice were subjected to CCl4 which diluted into corn oil (1:5) intraperitoneal 
injection for 4 weeks at dose of 0.5 ml/kg body weight twice a week. Mice were sacrificed 48 h after last dose of 
CCl4 administration.
Microarray studies. Human liver microarray studies were performed as previously  described35. For mouse 
microarray, liver tissue was collected from BALB/c WT and Lcn2−/− mice treated with CCl4 or corn oil for 
4  weeks. Total RNA was isolated and the integrity and purity were determined. Complementary DNA were 
labelled with Fluoresce Cy3 and hybridized to SurePrint G3 mouse gene expression chip slide (Agilent, G4852B). 
The arrays were scanned and analyzed for a digital probe count comparison. Quantile normalization, multi-
dimensional scaling, principal component analysis and hierarchical clustering were performed using base R 
functions. Differential expression analysis were performed by means of limma  package50. In order to analyze 
RNA expression differences between WT and Lcn2−/− mice treated with CCl4, Benjamini–Hochberg was used 
as an adjustment method for multiple comparisons. For gene set enrichment analysis (GSEA) top 2000 up and 
downregulated annotated probes were used. Probe annotation was made by using Agilent probe identification 
information 028,005-D gene list, version 20,171,030. Heatmaps of top differentially expressed genes (DEG) and 
of selected lists of genes was performed by using heatmap.2 function of gplots package. GSEA analysis included 
the DEG overlap with Molecular Signatures Database gene sets (Broad Institute, v 6.1), computed by using GSEA 
on-line web tool. Hypergeometric distribution was calculated to detect most enriched gene sets. We focused our 
analysis on Canonical Pathway gene sets, from Curated Gene Sets  collection51.
RNA sequencing. RNA sequencing was performed using Illumina HiSeq2000 platform (San Diego, CA) 
in human liver samples as described  previously46. Total RNA samples were also obtained from transduction 
with adenovirus vectors containing either human LCN2 or a GFP sequence in human primary hepatocytes and 
HepG2 cells.
Cell culture. Human primary hepatic stellate cells (HSCs). Human primary HSCs purchased from Scien-
Cell Research Laboratories (Catalog #5300) was isolated and purified from human liver. The cells were seeded 
and cultured according to manufacturer’s instruction. Transduction with adenovirus vectors containing either 
human LCN2 (Ad-LCN2, MOI = 10, 50) or a GFP sequence (Ad-GFP) (Signagen, SL112614) were performed 
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on HSCs for 48 h. To knockdown HIF1A gene expression, transfection with 50 nM either scrambled or HIF1A 
small interfering RNA (Thermo Fisher Scientific, AM16708A) for 48 h were performed with jetPRIME transfec-
tion reagent.
ChIP‑qPCR analysis. chromatin DNA was prepared using EpiTect ChIP Kit (Qiagen, 334471). Briefly, cells 
were transduced with GFP- or LCN2- expressing adenovirus and cultured for 72 h. Then cells were treated with 
1% formaldehyde at 37 °C to cross-link proteins to DNA. The samples were sonicated to fragments (Branso Digi-
tal Sonifer, model 102c). Anti-HIF1A (H1alpha67) monoclonal antibody (Thermo Fisher Scientific, MA116511) 
was used to immunoprecipitate binding fragments. Control IgG and polymerase II monoclonal antibody (Qia-
gen, 334481) was used as a negative and positive control respectively. The precipitated chromatin was then 
treated with proteinase K to reverse cross-links. DNA was subjected to real-time PCR with primers for human 
EDN1 gene promoter (Qiagen, GPH1011088 (-) 01A) or positive control (Qiagen, GPH110001C( +)01A) with 
SYBR Green ROX Mastermix (Qiagen, 33052).
Immunohistochemistry (IHC) and immunofluorescence (IF) staining. Human liver specimens 
from patients with AH and healthy liver fragments, and mouse liver sections were used to study LCN2 expres-
sion. IHC was performed using the Bond Fully-automated Slide Staining System. Slides were dewaxed in Bond 
Dewax solution and hydrated in Bond Wash solution. Heat-induced antigen retrieval was performed for 30 min 
at 100 °C in Bond-Epitope Retrieval solution 1 pH 6.0 (Leica Biosystems, AR9961). Antigen retrieval was fol-
lowed by 5 min Bond peroxide blocking step. After pretreatment, slides were incubated with primary antibody 
anti-LCN2. Chromogenic detection of antibodies was performed using the Bond Polymer Refine Detection 
System (Leica Biosystems, DS9800). Positive and negative controls were included for each run.
Dual IF staining was performed in the same system except antigen retrieval for F4/80 in Bond enzyme1 
(Leica Biosystems, AR9551) for 5 min at 37 °C. The primary antibodies information is shown in the Supple-
mental Table 3. Stained slides were counterstained nwith Hoechst 33,258 and mounted with ProLong Diamond 
Antifade Mountant.
Serum LCN2 and ET1 determination. Serum was obtained through peripheral blood extraction from 
patients with AH (n = 26), HCV (n = 24), NASH (n = 23), compensated alcoholic cirrhosis (n = 17) and healthy 
controls (n = 30). The samples were analyzed following the instructions provided from the Quantikine ELISA 
human LCN2 immunoassay kit (R&D Systems, DLCN20) and ET1 Immunoassay kit (R&D Systems, DET100).
Statistical analyses. Results of quantitative variables are expressed as mean ± SEM unless otherwise speci-
fied. Statistical analysis was performed using GraphPad Prism 7 software. Comparisons between groups were 
performed using the Student’s t test or one-way ANOVA. Correlations between variables were evaluated using 
Spearman’s rho or Pearson’s r, when appropriate. A p value less than 0.05 was considered statistically significant.
Data availability
The microarray data has been deposited in NCBI’s Gene Expression Omnibus (GEO) under Accession Number 
GSE130123. The RNA sequencing data has been deposited in NCBI GEO under Accession Number GSE130128.
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